StockLearn from Clustermicro · Stock Breakout ScannerStockLearn
← All NSE stocks

Balaxi Pharmaceuticals (BALAXI)

Pharma · NSE · end-of-day 2026-11-17
Close
₹26.47
Day change
+19.99%
1-year
-36.7%
From 52-week high
-36.6%
Weinstein stage
Stage 2
Minervini template
4/8
Balaxi Pharmaceuticals closed at ₹26.47 on 2026-11-17, down 26% over the past year, 37% below its 52-week high. It meets 4 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 2 - advancing. Over the year its annualised volatility was about 53%, with a largest fall of 63% from a peak.

Price, RSI and MACD

Price · +7.6% over the period
1921242729May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
RSI (14) · 70.5
305070
MACD (12, 26, 9) · histogram +0.56
-1-0.40.20.81.5
Price · -36.6% over the period
1423334252Nov 25Jan 26Mar 26May 26Jul 26Sep 26Nov 26
RSI (14) · 70.5
305070
MACD (12, 26, 9) · histogram +0.56
-3.2-1.8-0.412.4
Price · -70.6% over the period
11386491118Feb 25Jun 25Oct 25Feb 26Jun 26Oct 26
RSI (14) · 70.5
305070
MACD (12, 26, 9) · histogram +0.56
-6-3.7-1.40.93.3
Price · -68.7% over the period
104580115149Mar 24Aug 24Jan 25Jun 25Nov 25Apr 26Sep 26
RSI (14) · 70.5
305070
MACD (12, 26, 9) · histogram +0.56
-6.6-22.67.111.7
Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market capSales (TTM)Net profit (TTM)P/EEPS (TTM)P/BROEBeta
—————0.59—0.98

Investor methods

MethodChecksScoreVerdict
Minervini
✓ Close above the 150- and 200-day averages
✓ 150-day above 200-day
✗ 200-day rising for a month
✗ 50-day above the 150- and 200-day
✓ Close above the 50-day
✓ At least 25% above the 52-week low · low 15.67
✗ Within 25% of the 52-week high · high 41.72
✗ RS percentile 70 or more · RS 35
Minervini's trend template - the gate the scanner applies.
4/84 of 8
Weinstein
Stan Weinstein's stage analysis on the 30-week moving average.
Stage 2 - advancing
CAN SLIM
— C latest quarter EPS up 25%+, with sales up 25%+ or accelerating
— A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held
✗ N (proxy) near the 52-week high - within 15% · high 41.72
✓ S (proxy) more volume on up days than down days (50 sessions) · 1.03x
✗ L RS percentile 80 or more · RS 35
— I (proxy) FII + DII holding trend · not yet collected for this stock
✓ M (proxy) market in an uptrend, 40%+ of stocks above their 200-day - shared, not counted · breadth 51%
William O'Neil's growth-leader checklist, as a checklist score: the six stock letters counted equally, though O'Neil read them together. M is the market condition, shown but not counted. N, S, I and M are proxies.
1/3Weak
Darvas
✗ New 52-week high in the last 120 sessions
Darvas needs a new 52-week high to start a box.
10/100No box
Turtle
✗ Close above the prior 55-session high · 26.99
✓ Close above the prior 20-session high · 25.55
✗ Close below the prior 20-session low (also a Turtle exit level) · 18.70
Turtle-inspired long breakout: the Turtle traders' entry channels only - no exits, stops or position sizing.
Breakout (20-day)
Graham
Needs positive earnings and book value.
Not assessable
Each method's own rules, applied to this stock - shown as information, not a buy or sell signal. All were tested on available data.

Pharma sector — top 10 by 1-year return

Stock1M %3M %6M %1Y %3Y %5Y %P/EP/BROE %ROCE %ROA %D/EEV/EBITDA₹ CrSales TTM ₹ CrProfit TTM ₹ CrEPSBeta
BALAXI this stock+19.8+9.3+2.3-26.3-68.2-76.1—0.59—————————0.98
BLISSGVS+0.7+26.1+136.4+301.9+405.5+549.543.15.4111.516.89.650.0024.86,9791,07416615.20.90
INDSWFTLAB-7.6+6.0+147.9+233.3+252.7+338.434.01.963.23.92.660.0119.82,886753849.80.60
VENUSREM-7.6-15.4+67.3+174.9+341.6—16.82.8916.821.913.100.0011.02,03983712291.00.87
BAFNAPH+2.5+83.5+249.6+161.1+492.4+229.597.310.8412.311.96.760.3653.21,119155124.90.37
SHILPAMED-2.2+13.3+91.7+144.7+388.1+224.553.76.519.811.46.940.2433.817,9421,84233217.10.74
ACUTAAS+23.0+23.3+44.4+130.7+624.3+690.773.517.3824.031.720.170.0049.632,2811,59243953.60.68
LAURUSLABS+13.5+29.2+76.6+128.8+532.1+383.194.220.8418.217.98.970.4166.81.26L7,8221,33224.80.66
RUBICON+11.6-6.4+75.2+126.9——85.419.6822.6——0.2854.227,8742,10032519.70.34
IOLCP-2.0+18.3+80.0+99.4+124.8+99.127.62.917.910.75.540.1015.75,5992,7512036.91.04
SAILIFE+26.1+23.7+60.6+99.1——98.513.8415.120.910.280.1753.537,2052,37237617.80.82
Returns are total over each period, not annualised - 5Y is the whole five-year change. A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Bharat ParenteralsIndo Us BiotechMedico RemediesNectar LifesciencesLyka LabsAarey Drugs & PharmaceuticalsMedicamen BiotechHaleos Labs

← All NSE stocks  ·  More Pharma stocks

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →
Prices as of 2026-11-17, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.
For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.